Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 6,220

Document Document Title
WO/2006/010362A1
The invention relates to 1-amino adamantane derivatives and 3-amino adamantane-1-carboxylic acid derivatives, wherein the 5th and/or 7th position of the adamantane base frame can be substituted in any particular manner. The invention als...  
WO/2006/011420A1
Disclosed is a compound represented by the general formula (1) below. (1) [In the formula, R represents a hydrogen atom or a lower alkyl group; X represents a sulfur atom or an oxygen atom; Y represents a chain, branched or cyclic alkyl ...  
WO2005113511A9
The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods fo...  
WO/2006/006725A1
The present invention provides a reversible thermosensitive recording medium including a support and a thermosensitive recording layer thereon, in which the thermosensitive recording layer comprises an electron-donating coloring compound...  
WO/2006/003923A1
Disclosed is an excellent LXR modulator. Specifically disclosed are compounds represented by the following general formula (I). (In the formula, R1 represents -COR9 (wherein R9 represents an alkyl, an optionally substituted alkoxy or an ...  
WO/2006/002474A1
Benzoyl urea derivatives that are alpha helical peptide mimetics that mimic BH3-only proteins, compositions containing them, their conjugation to cell-targeting moieties, and their use in the regulation of cell death are disclosed. The b...  
WO/2005/123666A1
The invention relates to compounds of formula (I), wherein R e R1, R2, X and n are as defined in the description, and their use for the preparation of pharmaceutical compositions for the treatment of inflammatory states.  
WO2004098512A3
The present application describes modulators of MCP 1 of formula (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.  
WO/2005/122379A2
The present invention provides a 4ß1 integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unna...  
WO2005061443A3
The invention relates to benzoyl-substituted phenylalanine amides of formula (I), wherein the variables R<1> to R<15> have the meanings indicated in the description, the agriculturally useful salts thereof, methods and intermediate produ...  
WO/2005/114331A1
A resist composition which comprises one or more resist compounds (A) satisfying all of the requirements of (a) having, in the molecule thereof, at least one crosslinking group undergoing a crosslinking reaction directly or indirectly by...  
WO/2005/113511A1
The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods fo...  
WO2005082862A3
The present invention relates to benzimidazolyl derivatives of formula (I), with the definitions of R<8>, p, Ar<1>, E, D, R<9>, q and R<10> according to claim 1, the use of the compounds of formula (I) as inhibitors of one or more kinase...  
WO/2005/107762A2
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.  
WO/2005/108352A1
The invention relates to novel biaromatic compounds which correspond to the following general formula (I) and to their method of preparation and to their use in pharmaceutical compositions intended for use in human or veterinary medicine...  
WO/2005/108370A1
It is intended to provide benzene compounds represented by the following formulae and analogs thereof which exert an ACC activity inhibitory effect and are efficacious in treating hyperlipemia, fatty liver, impaired glucose tolerance, di...  
WO/2005/105737A1
The present invention relates to novel processes for the preparation of substituted tetralin and substituted indane derivatives. The present invention is further directed to novel processes for the preparation of intermediates in the pre...  
WO/2005/097737A1
The invention relates to a method for producing polyisocyanate prepolymers comprising allophanate structural units, using zinc compounds as catalysts and to the use of said prepolymers for producing polyurethanes and polycarbamides.  
WO/2005/097773A1
The present invention is related to carboxylic acids of Formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and...  
WO2005058798A8
Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.  
WO/2005/095333A1
The present invention relates to polymorphic forms of (1-&lcub 3-[3-(4-cyano-3-methoxy-phenyl)ureido]-phenyl&rcub -ethyl)-carbamic acid-2-cyano-1-ethyl-ethyl ester, processes therein, pharmaceutical compositions thereof, and uses therewith.  
WO/2005/092843A1
This invention relates to novel urea derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases ...  
WO/2005/092841A1
The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invent...  
WO/2005/090288A1
The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invent...  
WO2005070871A3
The application relates to novel amino alcohols of general formula (I) where R, R1, R2, R3, R4, R5, X1 and X2 each have the definitions illustrated in detail in the description, to a process for their preparation and to the use of these ...  
WO/2005/087215A1
The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating at least one disease, disorder, and condition associated with amyloidosis. Amyloidosis refers to a collection of d...  
WO2005056520A8
This invention relates to a group of novel somatostatin receptor subtype 1 (SSTR1) active compounds and pharmaceutical compositions comprising said compounds. Furthermore, the invention concerns the use of said compounds for the treatmen...  
WO/2005/085180A1
A novel method of an amidocarbonylation reaction among an aldehyde compound, an amide compound, and carbon monoxide, which comprises using a palladium-supporting crosslinked-polymer composition containing palladium clusters having a majo...  
WO/2005/082862A2
The present invention relates to benzimidazolyl derivatives of formula (I), with the definitions of R8, p, Ar1, E, D, R9, q and R10 according to claim 1, the use of the compounds of formula (I) as inhibitors of one or more kinases, the u...  
WO/2005/075410A1
Compounds of formula (I), for clinical treatment of autoimmune diseases, inflammatory diseases, organ transplant rejection and malignant neoplasia. A pharmaceutical composition comprising a compound of formula (I) in an amount giving a d...  
WO/2005/070871A2
The application relates to novel amino alcohols of general formula (I) where R, R1, R2, R3, R4, R5, X1 and X2 each have the definitions illustrated in detail in the description, to a process for their preparation and to the use of these ...  
WO2005040355A3
The invention provides compounds and methods for inhibition of kinases, such as those of the TAO family, more specifically KIAA1361, TAO, and JIK kinases. The invention provides compounds for modulating protein kinase enzymatic activity ...  
WO/2005/068417A1
A triphenylmethane derivative represented by the general formula (1), an organic gallant containing the derivative, an organic gel, and an organic fiber. Although the triphenylmethane derivative is a low-molecular compound, it has the ab...  
WO/2005/068420A1
The present invention relates to novel urea and thiourea compounds, compositions comprising urea or thiourea compounds, and methods useful for treating and preventing aging, Alzheimer’s Disease, cancer, cardiovascular disease, diabetic...  
WO2004050609A8
The invention provides compounds of formula I: useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and...  
WO/2005/063699A1
The present invention provides N-aryloxypropanolyl-N’-phenethyl-urea derivatives of formula (3), method for their preparation and use thereof as potent appetite suppressants for treatment of obesity. Formula (3): wherein R is selected ...  
WO/2005/063222A1
An Hsp90 family protein inhibitor which contains as an active ingredient a benzene derivative represented by the following general formula (I), a prodrug thereof, or a pharmacologically acceptable salt of either.  
WO/2005/063018A1
Present invention relates to a haloalkene compound of the formula (I)or its salt: wherein each of X1 and X2 is halogen; Y is alkyl, haloalkyl or phenyl; n is 0 to 5; L is -C(=B)Q, -C(=B)B’Q, -C(=B)N(D)Q, -N(D)Q, -N(D)C(=B)Q, -N(D)C(=B)...  
WO/2005/061445A1
Methods and reagents for rhodium-promoted carbonylation via isocyanate using carbon-isotope labeled carbon monoxide are provided. The resultant carbon­ isotope labeled compounds are useful as radiopharmaceuticals, especially for use in ...  
WO/2005/061443A2
The invention relates to benzoyl-substituted phenylalanine amides of formula (I), wherein the variables R1 to R15 have the meanings indicated in the description, the agriculturally useful salts thereof, methods and intermediate products ...  
WO2005020899A3
The present application describes modulators of MCP-1 of formula (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.  
WO/2005/058798A2
Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.  
WO2005033230A3
Low-cure powder coating compositions are disclosed, comprising at least one epoxy-­containing resin and/or at least one siloxane-containing resin, and at least one material having the structure formula (I) wherein R1 is an organic radic...  
WO/2005/056519A1
The present invention provides a compound represented by the formula (I): (INSERT CHEMICAL FORMULA) (wherein R1 is a lower alkyl substituted by a lower alkoxy or a heterocyclic group, or a heterocyclic group; R2 is a lower alkyl optional...  
WO/2005/056520A1
This invention relates to a group of novel somatostatin receptor subtype 1 (SSTR1) active compounds and pharmaceutical compositions comprising said compounds. Furthermore, the invention concerns the use of said compounds for the treatmen...  
WO2005037798A3
The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of pain and disorders related thereto as well as a method for trea...  
WO2005009943A3
The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms...  
WO2004052845A8
This invention relates to tetrahydro-naphthalene derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent acti...  
WO2005028445A3
Compounds of formula (I): wherein A, B and D are each C, N, O or S; E is C or N; the dotted circle within the five-membered ring indicates that the ring may be unsaturated or partially saturated;. R <1> is halogen, hydroxy, C 1-6 álkyl,...  
WO/2005/047249A1
The present invention relates to compounds which are CCR-5 receptor antagonists of the general formula (I) wherein R1, R2, R3, R4, Ra, Rb, Rc, Rd, X, m and n are as defined herein. The invention further comprises pharmaceutical compositi...  

Matches 551 - 600 out of 6,220